Caption Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.1M Hold
150,000
– – 0.09% 223
2026
Q2
$18.4M Buy
150,000
+25,200
+20% +$2.63M 0.09% 250
2026
Q1
$13.2M Sell
124,800
-50,000
-29% -$4.43M 0.08% 276
2025
Q4
$15.3M Buy
174,800
+156,800
+871% +$12.8M 0.1% 234
2025
Q3
$1.2M Sell
18,000
-117,000
-87% -$6.65M 0.01% 1044
2025
Q2
$7.46M Sell
135,000
-153,600
-53% -$7.37M 0.08% 287
2025
Q1
$14M Buy
+288,600
New +$12.1M 0.13% 137
2023
Q3
– Sell
-290,500
Closed -$8.02M – 1493
2023
Q2
$8.02M Buy
290,500
+265,500
+1,062% +$6.64M 0.14% 177
2023
Q1
$575K Buy
+25,000
New +$420K 0.01% 760
2022
Q3
– Sell
-548,700
Closed -$4.34M – 1781
2022
Q2
$4.34M Sell
548,700
-47,300
-8% -$572K 0.06% 404
2022
Q1
$14.1M Buy
596,000
+579,100
+3,427% +$16.3M 0.17% 140
2021
Q4
$577K Sell
16,900
-220,600
-93% -$6.97M 0.01% 1216
2021
Q3
$4.21M Buy
+237,500
New +$10.1M 0.05% 523

Other funds holding PTGX

Caption Management's PTGX Position: Q3 2026 in Review

Caption Management reduced its Protagonist Therapeutics (PTGX) stake by 29% in Q3 2026, selling an estimated $1.85M and leaving 32,000 shares worth $4.51M. The position accounts for 0.02% of the portfolio, ranked #698.

Caption Management first reported a position in PTGX in Q3 2021 and has held it in 12 quarters since. The position peaked at $6.59M in Q4 2021. 379 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Caption Management held 32,000 shares of Protagonist Therapeutics worth $4.51M as of Q3 2026.
  • Caption Management sold 13,000 Protagonist Therapeutics shares in Q3 2026, an estimated $1.85M.
  • Protagonist Therapeutics made up 0.02% of Caption Management's portfolio in Q3 2026, its #698 holding.
  • Caption Management first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Caption Management's Protagonist Therapeutics position peaked at $6.59M in Q4 2021.
  • 379 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Caption Management's 13F filing for Q3 2026, filed 16 Nov 2026.